Galectin-3 activates spinal microglia to induce inflammatory nociception in wild type but not in mice modelling Alzheimer's disease.
George Sideris-LampretsasSilvia OggeroLynda ZeboudjRita SilvaArchana BajpaiGopuraja DharmalingamDavid A CollierMarzia MalcangioPublished in: Nature communications (2023)
Musculoskeletal chronic pain is prevalent in individuals with Alzheimer's disease (AD); however, it remains largely untreated in these patients, raising the possibility that pain mechanisms are perturbed. Here, we utilise the TASTPM transgenic mouse model of AD with the K/BxN serum transfer model of inflammatory arthritis. We show that in male and female WT mice, inflammatory allodynia is associated with a distinct spinal cord microglial response characterised by TLR4-driven transcriptional profile and upregulation of P2Y12. Dorsal horn nociceptive afferent terminals release the TLR4 ligand galectin-3 (Gal-3), and intrathecal injection of a Gal-3 inhibitor attenuates allodynia. In contrast, TASTPM mice show reduced inflammatory allodynia, which is not affected by the Gal-3 inhibitor and correlates with the emergence of a P2Y12 - TLR4 - microglia subset in the dorsal horn. We suggest that sensory neuron-derived Gal-3 promotes allodynia through the TLR4-regulated release of pro-nociceptive mediators by microglia, a process that is defective in TASTPM due to the absence of TLR4 in a microglia subset.
Keyphrases
- neuropathic pain
- spinal cord
- toll like receptor
- inflammatory response
- wild type
- spinal cord injury
- chronic pain
- immune response
- oxidative stress
- high fat diet induced
- mouse model
- nuclear factor
- end stage renal disease
- ejection fraction
- gene expression
- lipopolysaccharide induced
- magnetic resonance
- transcription factor
- cognitive decline
- lps induced
- type diabetes
- prognostic factors
- insulin resistance
- computed tomography